Table 3.
Dosimetric and geometric outcomes in initial cohort (N = 200)
| Characteristic | Result |
|---|---|
| Minimum skin spacing, mm | |
| Mean (std) | 10.34 (8.8) |
| Median | 8.25 |
| Range | [1.3-76.4] |
| Minimum rib spacing, mm | |
| Mean (std) | 15.0 (15.9) |
| Median | 9.45 |
| Range | [1.0-99.3] |
| Skin dose, % of PD | |
| Median | 80 |
| Range | [20.8-113] |
| Rib dose, % of PD | |
| Median | 75 |
| Range | [0-114.2] |
| V100, cm3 | |
| Mean (std) | 89.5 (54.6) |
| Median | 77.45 |
| Range | [4.95-349.9] |
| V150, cm3 | |
| Mean (std) | 24.2 (8.6) |
| Median | 24.6 |
| Range | [0-39.6] |
| V200, cm3 | |
| Mean (std) | 10.2 (4.2) |
| Median | 10.3 |
| Range | [0-22.3] |
| %PD to 100% of PTV eval | |
| Mean (std) | 71.1 (13.3) |
| Median | 72.05 |
| Range | [0-97.3] |
| %PD to 95% of PTV eval | |
| Mean (std) | 93.3 (9.2) |
| Median | 94.8 |
| Range | [0-106] |
| %PD to 90% of PTV eval | |
| Mean (std) | 99.1 (5.4) |
| Median | 99.75 |
| Range | [82-111] |
| Volume of PTV eval, cm3 | |
| Mean (std) | 97.1 (55.5) |
| Median | 84.96 |
| Range | [16.7-386.1] |
Abbreviations: PD = prescription dose; PTVeval = planning target volume as defined in NSABPB39/RTOG0413; std = standard deviation; V100 = volume of breast tissue receiving 100% of the prescribed dose; V150 = volume of breast tissue receiving 150% of the prescribed dose; V200 = volume of breast tissue receiving 200% of the prescribed dose.